摘要
【摘要】目的 探讨普拉克索与多巴丝肼联合治疗老年帕金森病的临床效果。方法 选择我院在 2018年 1月～ 2019年 8月所收治的 54例老年帕金森病患者，按药物的不同将其分为单一组（予以普拉克索治疗）和联合组（予以普拉克索和多巴丝肼治疗），各 27例。对比两组治疗前后的血清同型半胱氨酸（ Hcy）水平、胰岛素样生长因子 1（ IGF-1）水平、帕金森综合评分量表（ UPDRS）评分。结果 经治疗，联合组血清 Hcy水平、 UPDRS评分低于单一组，差异有统计学意义（ P<0.05），联合组的 IGF-1水平高于单一组，差异有统计学意义（ P<0.05）。结论 将普拉克索与多巴丝肼应用至老年帕金森病患者的治疗中，能有效降低血清 Hcy水平，提升血清 IGF-1水平，促进患者身体康复。
【关键词】普拉克索 ;多巴丝肼 ;老年帕金森病
[Abstract] Objective To investigate the clinical effect of pramipexole combined with dopa in the treatment of senile Parkinson's disease. Methods a total of 54 elderly patients with Parkinson's disease in our hospital from January 2018 to August 2019 were selected and divided into single group (treated with pramipexole) and combined group (treated with pramipexole and DOPA hydrazide), 27 cases in each group. The levels of serum homocysteine (Hcy), insulin-like growth factor-1 (IGF-1) and Parkinson's syndrome score (UPDRS) were compared between the two groups before and after treatment. Results after treatment, the serum Hcy level and UPDRS score in the combined group were lower than those in the single group (P < 0.05), and the IGF-1 level in the combined group was higher than that in the single group (P < 0.05). Conclusion pramipexole and DOPA can effectively reduce the serum Hcy level, improve the serum IGF-1 level, and promote the recovery of patients.
出版日期
2020年09月21日（中国期刊网平台首次上网日期，不代表论文的发表时间）
